OBJECTIVE: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. DESIGN: Double-blind, placebo-controlled clinical trial. SETTING:Academic medical centers. PARTICIPANTS: Subjects with mild to moderate Alzheimer disease. INTERVENTION: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. MAIN OUTCOME MEASURES: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale). RESULTS:Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau(181) levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. CONCLUSIONS:Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00117403.
RCT Entities:
OBJECTIVE: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. DESIGN: Double-blind, placebo-controlled clinical trial. SETTING: Academic medical centers. PARTICIPANTS: Subjects with mild to moderate Alzheimer disease. INTERVENTION: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. MAIN OUTCOME MEASURES: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale). RESULTS: Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau(181) levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. CONCLUSIONS: Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00117403.
Authors: C Hesse; L Rosengren; N Andreasen; P Davidsson; H Vanderstichele; E Vanmechelen; K Blennow Journal: Neurosci Lett Date: 2001-01-19 Impact factor: 3.046
Authors: L J Thal; M Grundman; J Berg; K Ernstrom; R Margolin; E Pfeiffer; M F Weiner; E Zamrini; R G Thomas Journal: Neurology Date: 2003-12-09 Impact factor: 9.910
Authors: Clifford W Shults; David Oakes; Karl Kieburtz; M Flint Beal; Richard Haas; Sandy Plumb; Jorge L Juncos; John Nutt; Ira Shoulson; Julie Carter; Katie Kompoliti; Joel S Perlmutter; Stephen Reich; Matthew Stern; Ray L Watts; Roger Kurlan; Eric Molho; Madaline Harrison; Mark Lew Journal: Arch Neurol Date: 2002-10
Authors: Thomas J Montine; M Diana Neely; Joseph F Quinn; M Flint Beal; William R Markesbery; L Jackson Roberts; Jason D Morrow Journal: Free Radic Biol Med Date: 2002-09-01 Impact factor: 7.376
Authors: Jose M Rubio-Perez; Maria D Albaladejo; Pilar Zafrilla; Maria L Vidal-Guevara; Juana M Morillas-Ruiz Journal: Eur J Nutr Date: 2015-08-23 Impact factor: 5.614
Authors: A M Alavi Naeini; I Elmadfa; A Djazayery; M Barekatain; M R Aghaye Ghazvini; M Djalali; A Feizi Journal: Eur J Nutr Date: 2013-12-11 Impact factor: 5.614